Navigation Links
Senexis and O2H (Oxygen Healthcare) Announce Medicinal Chemistry Collaboration
Date:2/14/2008

CAMBRIDGE, England, February 14 /PRNewswire/ -- Executives from Senexis and O2H, both located in Cambridge, UK, announced an agreement under which O2H will provide synthetic and computational chemistry services to the drug discovery programmes at Senexis on an FTE basis.

"We believe our collaboration with O2H leverages the complementary expertise of both organisations and will benefit our search for new therapeutics to treat ageing-related diseases by helping Senexis increase the return on its chemistry research budget" said David Scopes, BSc, MSc, PhD - Chief Scientific Officer at Senexis.

Senexis, a recipient of recent Wellcome Trust funding, is a drug development company, dedicated to the discovery of effective treatments and diagnostics for major ageing-related diseases, such as Alzheimer's dementia, type II diabetes and dialysis related amyloidosis. It is now widely believed that the misfolding and aggregation of amyloid-like proteins underlies the pathologies of these different diseases. Senexis has discovered potent and selective compounds that protect cells and tissues from the toxic forms of amyloid. Senexis is funded by BTG plc and the Wellcome Trust. Further information on Senexis can be found at http://www.senexis.com

O2H has its global HQ in the Science Park, Cambridge, UK, project offices in Boston and Tokyo, and a talented team of scientists in its world class discovery research centre in Ahmedabad, India. "Our scientific team in India with our project offices around the world helps our partners to maximise the value of their drug discovery programmes, from initial planning through to lead generation and lead optimisation thereby delivering enormous advantages to our growing portfolio of global clients," says Sunil Shah, CEO, O2H.

Further information on O2H can be found at http://www.oxygenhealthcare.com.

Please contact info@oxygenhealthcare.com

SENEXIS LIMITED OXYGEN HEALTHCARE LTD

Babraham Research Campus 23 Cambridge Science Park

Babraham, Cambridge, UK Cambridge, UK

CB22 3AT CB4 0EY

High resolution logos can be downloaded from http://www.oxygenhealthcare.com/senexis/logos.zip


'/>"/>
SOURCE Senexis and O2H (Oxygen Healthcare)
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results Teleconference and Webcast
2. GeoPharma Announces Record Revenues in Third Quarter Results
3. Angiotech announces results for the fourth quarter ended December 31, 2007
4. Cell Therapeutics, Inc. (CTI) Announces Cancellation of Approximately $9.1 Million of Existing Notes due 2008
5. Warner Chilcott Announces Earnings Release Date and Conference Call for Fourth Quarter and Full Year 2007 Financial Results
6. Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2007 Financial Results
7. NightHawk Radiology Holdings, Inc. Announces Senior Executive Departures
8. VLST Corporation Announces Board and Executive Management Appointments
9. Martek to Announce First Quarter 2008 Results on March 5, 2008
10. Advance Nanotech Announces Shareholder Proxy Vote Results
11. Cellegy Pharmaceuticals Announces Signing of Definitive Merger Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Eurofins announces the appointment of Sean Murray , ... Inc. (ESI). Mr. Murray will bring valuable expertise ... experience in leading international business teams. As the National Division Leader, ... uphold Eurofins, status as the global leader in bio-analytical testing services. ... , , ...
(Date:12/8/2016)...  Anaconda BioMed S.L., a pre-clinical stage medical device ... neuro-thrombectomy system for the treatment of Acute Ischemic Stroke ... to join its Scientific Advisory Board (SAB). The SAB ... scientific and clinical experts to Anaconda BioMed S.L., as ... ® to its clinical phase. The SAB is ...
(Date:12/8/2016)... 8, 2016  Soligenix, Inc. (OTCQB: SNGX) (Soligenix ... on developing and commercializing products to treat rare ... announced today the long-term follow-up data from its ... first-in-class Innate Defense Regulator (IDR), in the treatment ... cancer patients undergoing chemoradiation therapy (CRT).  The additional ...
(Date:12/8/2016)... , Dec. 8, 2016  Partnering to fuel ... Ben Franklin Technology Partners of Southeastern Pennsylvania ... ("IHG"), the parent company of Independence Blue Cross; and ... announced their intentions for a $6 million funding initiative ... healthcare startups. Responding to a burgeoning economic ...
Breaking Biology Technology:
(Date:11/19/2016)... 2016 Securus Technologies, a leading provider of ... investigation, corrections and monitoring, announced today that it has ... have an independent technology judge determine who has the ... tech/sophisticated telephone calling platform, and the best customer service. ... most of what we do – which clearly is ...
(Date:11/15/2016)... 15, 2016  Synthetic Biologics, Inc. (NYSE MKT: ... on the gut microbiome, today announced the pricing ... of its common stock and warrants to purchase ... price to the public of $1.00 per share ... from the offering, excluding the proceeds, if any ...
(Date:6/27/2016)... Research and Markets has announced the addition ... to their offering. The report ... to grow at a CAGR of 12.28% during the period 2016-2020. ... in-depth market analysis with inputs from industry experts. The report covers ... The report also includes a discussion of the key vendors operating ...
Breaking Biology News(10 mins):